In this article, we are going to take a look at where Blue Bird Corporation (NASDAQ:BLBD) stands against the other hot EV ...

MACON, Ga.--(BUSINESS WIRE)--Blue Bird Corporation (Nasdaq: BLBD), the leader in electric and low-emission school buses, commends the announcement by the U.S. Environmental Protection Agency (EPA ...

Fintel reports that on October 3, 2024, Roth MKM downgraded their outlook for Blue Bird (NasdaqGM:BLBD) from Buy to Neutral.

But one company that largely stood out was Blue Bird Corporation. As I detailed in my prior article on the company, it provides customers with school buses and parts related to them. Examples ...

Company Continues to Invest in Electric School Bus Manufacturing Expansion and ... in this press release regarding earnings growth and Blue Bird’s future positioning and may include other ...

Blue Bird Corporation is an American company, which together with its subsidiaries is primarily engaged in designing, engineering, manufacturing, and selling school buses and related parts across ...

Company Continues to Invest in Electric School Bus Manufacturing Expansion and Job Growth MACON, Ga., October 01, 2024--(BUSINESS WIRE)--Blue Bird Corporation (Nasdaq: BLBD), the leader in ...

Update on Sept 13, 2024. American Express confirmed that Bluebird no longer offers new Goal balances or new family sub-accounts. The Bluebird card, offered by American Express, is an FDIC-insured ...

AT&T's Head of Network Chris Sambar talks about the carrier's plan to use the BlueBird satellites to bring connectivity to phones. He also calls out SpaceX, a rival to AST SpaceMobile.

The Falcon 9's upper stage carried the BlueBird satellites into low Earth orbit as planned and successfully deployed them over a 14-minute stretch beginning about 54 minutes after liftoff.

SOMERVILLE, Mass., October 04, 2024--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of inducement awards ...

bluebird bio is pricing its thalassaemia gene therapy Zynteglo at €1.57 million ($1.8 million) in Europe, but with an outcomes-based payment scheme to try to persuade healthcare systems to allow ...